LDX LUMOS DIAGNOSTICS HLDGS LTD

Liverpool CCG and Community Pharmacy Liverpool Launch FebriDx® Service at More Than 100 Community Pharmacies

Today, Liverpool Clinical Commissioning Group (CCG) and Community Pharmacy Liverpool kicked off a new clinical service that will allow more than 100 pharmacies to offer a 10-minute, point-of-care test to differentiate bacterial from viral respiratory infection.

This press release features multimedia. View the full release here:

Now available at 100+ pharmacies across Liverpool, the FebriDx point-of-care test detects and differentiates bacterial v. viral respiratory infections in 10 minutes. The FebriDx test will be used for patients with an acute cough at pharmacies under a new minor ailments service known as Pharmacy First, to enable rapid diagnoses and appropriate antibiotic prescribing – without the need for a GP appointment first. (Photo: Business Wire)

Now available at 100+ pharmacies across Liverpool, the FebriDx point-of-care test detects and differentiates bacterial v. viral respiratory infections in 10 minutes. The FebriDx test will be used for patients with an acute cough at pharmacies under a new minor ailments service known as Pharmacy First, to enable rapid diagnoses and appropriate antibiotic prescribing – without the need for a GP appointment first. (Photo: Business Wire)

The test, named FebriDx®, will be used for patients with an acute cough at pharmacies across Liverpool under a new minor ailments service known as Pharmacy First, to enable rapid diagnoses and appropriate antibiotic prescribing – without the need for a GP appointment first.

“It is often difficult for healthcare providers to determine if a respiratory infection is bacterial or viral without this type of rapid testing because the symptoms are nearly identical,” said Peter Johnstone, Head of Medicines Optimisation for Liverpool CCG.

“FebriDx lends itself to the Pharmacy First initiative really well – the test uses a small finger stick blood sample to differentiate a bacterial from viral acute respiratory infection in just 10 minutes, and we’re starting to offer this in local pharmacies to help ensure people get the right treatment.”

The has already been in use in some hospitals and GP Surgeries across the UK for three years, but this is the first time it has been used in the Merseyside region.

“Our goal is to provide patients with more convenient access to testing and treatment for acute cough under a new Patient Group Direction (PGD),” explains Matt Harvey, Chief Officer of Community Pharmacy Liverpool. “With the high volumes of patients with coughs and respiratory problems during the winter season, we see a real opportunity to bring this test into local pharmacies to help us provide treatment for patients more quickly – without the need for a GP appointment or prescription first.”

In addition to the convenience, clinical studies show that this test allows healthcare providers to rule out bacterial infections for their patients with 99% confidence, which can help reduce the unnecessary use of antibiotics and reduce antimicrobial resistance.

To learn more about this service, please visit:

About NHS Liverpool CCG

NHS Liverpool Clinical Commissioning Group (CCG) is responsible for commissioning (planning and buying) hospital and community health services for the people of Liverpool. It has a budget of around £840m a year. The CCG is made up of representatives from each of the city’s 85 GP practices, and is led by a Governing Body consisting of GPs from across the city. Visit the website at:

About Community Pharmacy Liverpool

Community Pharmacy Liverpool is Liverpool’s local pharmaceutical committee (LPC), an organisation which represents community pharmacies across the city. Visit the website at:

EN
12/01/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LUMOS DIAGNOSTICS HLDGS LTD

 PRESS RELEASE

Lumos Diagnostics Appoints Doug Ward as CEO

Lumos Diagnostics Appoints Doug Ward as CEO Ward to lead U.S. FebriDx launch pending FDA 510(k) clearance SARASOTA, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- Lumos Diagnostics (ASX:LDX), a leader in rapid point-of-care (POC) diagnostic technologies, announced today that its Board of Directors has appointed Doug Ward, a highly experienced diagnostics executive, to serve as CEO. “We are delighted to welcome Doug Ward as the CEO of Lumos,” said Sam Lanyon, Executive Chair of Lumos Diagnostics and Co-founder of Planet Innovation. “He is a proven leader in the healthcare industry and this r...

 PRESS RELEASE

Le GCC de Liverpool et l’organisation Community Pharmacy Liverpool lan...

LIVERPOOL, Angleterre--(BUSINESS WIRE)-- Le groupe de commissionnement clinique (GCC) de Liverpool et l’organisation Community Pharmacy Liverpool ont lancé aujourd’hui un nouveau service clinique qui permettra à plus de 100 pharmacies de proposer un test au plus près du patient, pour différencier en 10 minutes une infection respiratoire bactérienne ou virale. Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : Now available at 100+ pharmacies across Liverpool, the FebriDx point-of-care test detects and differentiates bacterial v. viral respiratory infect...

 PRESS RELEASE

Liverpool CCG and Community Pharmacy Liverpool Launch FebriDx® Service...

LIVERPOOL, England--(BUSINESS WIRE)-- Today, Liverpool Clinical Commissioning Group (CCG) and Community Pharmacy Liverpool kicked off a new clinical service that will allow more than 100 pharmacies to offer a 10-minute, point-of-care test to differentiate bacterial from viral respiratory infection. This press release features multimedia. View the full release here: Now available at 100+ pharmacies across Liverpool, the FebriDx point-of-care test detects and differentiates bacterial v. viral respiratory infections in 10 minutes. The FebriDx test will be used for patients with an acute cough at ...

 PRESS RELEASE

Lumos Diagnostics Receives Authorization for CoviDx™ SARS-CoV-2 Rapid ...

MELBOURNE, Australia--(BUSINESS WIRE)-- Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that Health Canada has granted Interim Order authorization for the Lumos CoviDx™ SARS-CoV-2 Rapid Antigen Test. The CoviDx test gives qualified healthcare providers qualitative, easy-to-interpret results within 15-20 minutes in cases of suspected COVID-19 and when performing serial testing of asymptomatic patients. This press release features multimedia. View the full release here: The CoviDx test from Lumos Diagnostics gives qualified healthcare ...

 PRESS RELEASE

Economic Evaluation of Lumos Diagnostics’ FebriDx® Point-of-Care Test ...

SARASOTA, Fla.--(BUSINESS WIRE)-- Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that the Journal of Health Economics and Outcomes Research (JHEOR) has published an economic study that concludes using the FebriDx® test to guide antibiotic treatment for patients presenting with acute respiratory infections (ARIs) could potentially result in $2.5 billion of annual cost saving for the U.S. healthcare system. This press release features multimedia. View the full release here: The FebriDx point-of-care test from Lumos Diagnostics could r...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch